November 15, 2024

MM Clinical Advances From IMS 2024

Studies presented at the 21st International Myeloma Society (IMS) Annual Meeting, held September 25–28 in Rio de Janeiro, focused on several important areas: Improved outcomes with US Food and Drug Administration (FDA)–approved quadruplet therapies, such as daratumumab and isatuximab, for newly diagnosed multiple myeloma (NDMM) Updates on studies evaluating innovative maintenance approaches, including new combinations […]

November 2, 2024

Multiple Myeloma Workup: Approach Considerations, Blood Studies, Urine Collection – Medscape Reference

October 30, 2024

Living with multiple myeloma – Newsroom OSF HealthCare

October 29, 2024

Dr Dhakal on Notable Multiple Myeloma Trials Presented in 2024 – OncLive

October 29, 2024

Clinical Trial Utilizes Novel CAR Target for Relapsed/Refractory Multiple Myeloma – Roswell Park Comprehensive Cancer Center